Kalincik, T. Et Al. 2022. Comparative effectiveness of autologous haematopoietic stem cell transplantation vs. fingolimod, ocrelizumab and natalizumab in relapsing-remitting MS. 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis , (Amsterdam, Netherlands), 11-14.

Kalincik, T., Sharman, S., Roos, I., Freedman, M., Atkins, H., Burman, J., ... Massey, J.(2022). Comparative effectiveness of autologous haematopoietic stem cell transplantation vs. fingolimod, ocrelizumab and natalizumab in relapsing-remitting MS . 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (pp.11-14). Amsterdam, Netherlands

Kalincik, T. Et Al. "Comparative effectiveness of autologous haematopoietic stem cell transplantation vs. fingolimod, ocrelizumab and natalizumab in relapsing-remitting MS," 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Amsterdam, Netherlands, 2022

Kalincik, T. Et Al. "Comparative effectiveness of autologous haematopoietic stem cell transplantation vs. fingolimod, ocrelizumab and natalizumab in relapsing-remitting MS." 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis , Amsterdam, Netherlands, pp.11-14, 2022

Kalincik, T. Et Al. (2022) . "Comparative effectiveness of autologous haematopoietic stem cell transplantation vs. fingolimod, ocrelizumab and natalizumab in relapsing-remitting MS." 38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis , Amsterdam, Netherlands, pp.11-14.

@conferencepaper{conferencepaper, author={T. Kalincik Et Al. }, title={Comparative effectiveness of autologous haematopoietic stem cell transplantation vs. fingolimod, ocrelizumab and natalizumab in relapsing-remitting MS}, congress name={38th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis}, city={Amsterdam}, country={Netherlands}, year={2022}, pages={11-14} }